摘要
目的:探讨吡格列酮对早期糖尿病肾病患者血清淀粉样蛋白A(SAA)、β痕量蛋白(β-TP)及炎症因子水平的影响。方法:选取2017年1-12月本院收治的80例糖尿病肾病患者。按照随机数字表法将其分为试验组和观察组,各40例。对照组给予常规治疗,试验组在此基础上给予吡格列酮治疗。比较两组治疗前后的血清SAA、β-TP、IL-6、IL-18、TNF-α、hs-CPR水平。结果:治疗后,试验组血清SAA、β-TP水平均低于治疗前及对照组,比较差异均有统计学意义(P<0.05);治疗后,试验组IL-6、IL-18、TNF-α、hs-CPR水平均低于治疗前及对照组(P<0.05)。结论:吡格列酮能改善早期糖尿病肾病患者血清SAA、β-TP及炎症因子水平,延缓糖尿病肾病病程进展。
Objective:To discuss the effect of Pioglitazone on serum of amyloid A(SAA),β-trance protein components(β-TP)and inflammatory factors levels in patients with early diabetic nephropathy.Method:A total of 80 patients with early diabetic nephropathy in our hospitals from January to December 2017 were selected.According to the random number table method,they were divided into experimental group and observation group,40 cases in each group.The control group was given conventional treatment,while experimental group was given Pioglitazone on the basis of this treatment.The levels of serum SAA,β-TP,IL-6,IL-18,TNF-αand hs-CPR before and after treatment between two groups were compared.Result:After treatment,the levels of serum SAA andβ-TP in experimental group were lower than those of before treatment and control group,the differences were statistically significant(P<0.05).After treatment,the levels of IL-6,IL-18,TNF-αand hs-CPR in experimental group were lower than those of before treatment and control group,the differences were statistically significant(P<0.05).Conclusion:Pioglitazone can improve the levels of serum SAA,β-TP and inflammatory factors in patients with early diabetic nephropathy,and delay the progression of diabetic nephropathy.
作者
陈琳
陈文娜
官雯娟
CHEN Lin;CHEN Wenna;GUAN Wenjuan(Yingtan People’s Hospital,Yingtan 335000,China)
出处
《中国医学创新》
CAS
2018年第29期42-45,共4页
Medical Innovation of China
基金
江西省卫生计生委科技计划项目(20187347)
关键词
吡格列酮
糖尿病肾病
β痕迹蛋白
淀粉样蛋白A
炎症因子
Pioglitazone
Diabetic nephropathy
β-trance protein components
Amyloid A
Inflammatory factor
